Dechra Pharmaceuticals

Equities

DPH

GB0009633180

Delayed London S.E. Other stock markets 02:30:00 2024-01-16 EST			5-day change	1st Jan Change
3,866 ^GBX	-.--%		-.--%	+0.21%

06-10	Dechra Pharmaceuticals Limited Appoints Jonathan David Lang as Director	CI
04-15	Dechra Pharmaceuticals Limited acquired 33.34% stake in STEM Animal Health Inc.	CI

Dechra Pharmaceuticals plc Reports Group Revenue Results for the Six Months Ended December 31, 2017

January 09, 2018 at 08:17 am

Dechra Pharmaceuticals plc reported group revenue results for the six months ended December 31, 2017. For the six months, the reported group revenue increased by c.10.5% at constant exchange rate (CER) (c.11.5% at actual exchange rate (AER)).

Latest news about Dechra Pharmaceuticals

Dechra Pharmaceuticals Limited Appoints Jonathan David Lang as Director	06-09	CI
Dechra Pharmaceuticals Limited acquired 33.34% stake in STEM Animal Health Inc.	04-14	CI
Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million.	04-10	CI
Dechra Group Holdings Limited Appoints Paul Nicholas Sandland as Director	04-09	CI
Dechra Group Holdings Limited Appoints Ian David Page as Director	04-09	CI
Dechra Group Holdings Limited Announces Resignation of Thomas Spicer as Director	04-09	CI
Dechra Group Holdings Limited Announces Resignation of Anthony Santospirito as Director	04-09	CI
Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director	04-09	CI
Stocks slump as Fed rate cut hope dwindles	01-17	AN
Dechra Pharmaceuticals Delists From London Bourse Following Freya Bidco’s Takeover	01-17	MT
EQT's Freya Bidco Completes Dechra Pharmaceuticals Purchase	01-16	MT
Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 100 Index	01-16	CI
Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-World Index	01-16	CI
Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 350 Index	01-16	CI
Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-Share Index	01-16	CI
Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 350 (Ex Investment Companies) Index	01-16	CI
Dechra Pharmaceuticals PLC(LSE:DPH) dropped from S&P Global BMI Index	01-16	CI
EQT X EUR SCSp and EQT X USD SCSp managed by Eqt Fund Management S.à R.L. and Luxinva SA (the Offerors) completed the acquisition of Dechra Pharmaceuticals PLC.	01-15	CI
Persimmon to replace outbound FTSE 100 constituent Dechra	01-12	AN
EMEA Morning Briefing : Markets to Track Fresh Middle East Tensions	01-12	DJ
EU clears Dechra Pharmaceuticals takeover by EQT funds	12-27	AN
EQT's Dechra Takeover to Become Effective in Mid-January 2024	12-27	MT
EQT's Takeover of Dechra Pharmaceuticals Gets EU Antitrust Regulator's Nod	12-22	MT
Inchcape to appoint Jerry Buhlmann to chair board of directors from May	12-14	AN
EQT Secures Australian Nod for Dechra Pharmaceuticals Takeover	11-30	MT

Chart Dechra Pharmaceuticals

Duration

Period

More charts

Company Profile

Dechra Pharmaceuticals PLC specializes in the manufacturing and marketing of veterinary pharmaceutical products. Net sales break down by family of products as follows: - companion animal products (74.6%); - food producing animal products (11.5%); - equine health products (7.3%); - animal feeds (5.1%); - other (1.5%): products manufactured by third parties. Net sales are distributed geographically as follows: the United Kingdom (8.5%), Germany (9.2%), Europe (31.2%), the United States (37.9%) and other (13.2%).

Sector

More about the company

Income Statement Evolution

More financial data